NAPLEX Quiz: Medication And Non Drug Therapy Selection

What this quiz covers

This quiz focuses on Medication And Non Drug Therapy Selection, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Increase spironolactone to 50 mg by mouth daily to improve heart failure outcomes
2. Discontinue spironolactone and reassess potassium and renal function within 3–7 days (correct answer)
3. Add potassium chloride 20 mEq by mouth daily to prevent diuretic-related hypokalemia
4. Continue current regimen and recheck potassium in 6 months since blood pressure is controlled

Explanation: This question tests recognition and management of drug-induced hyperkalemia in a complex elderly patient. The key patient-specific factors are hyperkalemia (5.6 mEq/L), concurrent use of multiple potassium-increasing drugs (lisinopril, spironolactone), and NSAID use with reduced renal function. Discontinuing spironolactone is the best initial step because it directly increases potassium, and the combination with ACE inhibitor and NSAIDs creates dangerous synergy. Increasing spironolactone (A) would worsen hyperkalemia and risk cardiac arrhythmias. Adding potassium supplements (C) is contraindicated with existing hyperkalemia. Continuing current therapy (D) ignores a potentially life-threatening electrolyte abnormality requiring prompt intervention. The clinical pearl is that hyperkalemia risk increases exponentially when combining RAS inhibitors, potassium-sparing diuretics, and NSAIDs, especially in elderly patients with reduced renal function, requiring careful monitoring and often medication discontinuation to prevent cardiac complications.

Question 2

1. Start prednisone 40 mg by mouth daily for 5 days and doxycycline 100 mg by mouth twice daily for 5 days (correct answer)
2. Start fluticasone nasal spray 2 sprays per nostril daily only
3. Start propranolol 40 mg by mouth twice daily to reduce tachycardia
4. Discontinue tiotropium and use albuterol scheduled 2 puffs every 4 hours

Explanation: This question tests the management of acute exacerbations in chronic obstructive pulmonary disease (COPD). The key patient-specific factor is the presence of increased sputum volume and purulence with low-grade fever, indicating a bacterial exacerbation in a GOLD group D patient. Starting prednisone 40 mg daily for 5 days and doxycycline 100 mg twice daily for 5 days is the best choice as systemic corticosteroids and antibiotics are recommended for moderate to severe COPD exacerbations with purulent sputum. Starting fluticasone nasal spray addresses allergies but not the exacerbation; propranolol may worsen bronchospasm; discontinuing tiotropium and scheduling albuterol ignores the need for steroids and antibiotics. GOLD guidelines emphasize short-course steroids and antibiotics for exacerbations with infection signs to reduce hospitalization risk. Patient-centered care includes smoking cessation counseling and monitoring for antibiotic side effects to improve long-term outcomes.

Question 3

1. Start prednisone 40 mg by mouth daily for 5 days and azithromycin 500 mg once then 250 mg daily for 4 days (correct answer)
2. Start oseltamivir 75 mg by mouth twice daily for 5 days only
3. Start fluticasone/salmeterol and discontinue tiotropium to reduce duplication
4. Start amoxicillin/clavulanate 875/125 mg by mouth twice daily for 7 days without corticosteroids

Explanation: This question evaluates treatment selection for an acute COPD exacerbation with evidence of bacterial infection. The key patient-specific factors are purulent sputum, fever, and penicillin allergy requiring alternative antibiotic selection. The combination of prednisone and azithromycin is optimal because systemic corticosteroids reduce treatment failure and hospital admissions in COPD exacerbations, while azithromycin covers typical respiratory pathogens. Oseltamivir (B) treats influenza, not bacterial infections or COPD exacerbations. Starting fluticasone/salmeterol (C) during an acute exacerbation is inappropriate as maintenance therapy changes should occur when stable. Amoxicillin/clavulanate (D) is contraindicated due to penicillin allergy, and omitting corticosteroids reduces treatment effectiveness. The clinical framework emphasizes that moderate-to-severe COPD exacerbations require both systemic corticosteroids (typically 40 mg prednisone for 5 days) and antibiotics when bacterial infection is suspected, with antibiotic selection guided by local resistance patterns and patient allergies.

Question 4

1. Start atorvastatin 80 mg by mouth nightly (correct answer)
2. Start ezetimibe 10 mg by mouth daily as monotherapy
3. Start fenofibrate 160 mg by mouth daily
4. No lipid-lowering therapy is indicated because blood pressure is controlled

Explanation: This question tests lipid management in patients with hypertension and CKD. The key patient-specific factor is LDL-C 190 mg/dL with CKD stage 2, warranting high-intensity statin for risk reduction. Starting atorvastatin 80 mg nightly is appropriate as high-intensity statins are recommended for high-risk patients per ACC/AHA guidelines. Ezetimibe monotherapy is insufficient; fenofibrate targets triglycerides; no therapy ignores risk. Guidelines emphasize statins in CKD for cardiovascular protection. Patient-centered care includes exercise promotion and liver monitoring for safety.

Question 5

1. Switch hydrochlorothiazide to chlorthalidone 50 mg by mouth daily to improve blood pressure
2. Discontinue hydrochlorothiazide and add amlodipine 5 mg by mouth daily (correct answer)
3. Add indomethacin daily for gout prevention and continue current antihypertensives
4. Add spironolactone 50 mg by mouth daily without monitoring potassium

Explanation: This question tests therapy modification in hypertension with diuretic side effects. The key patient-specific factor is elevated uric acid and low-normal potassium likely from hydrochlorothiazide, contributing to gout risk. Discontinuing hydrochlorothiazide and adding amlodipine 5 mg daily is necessary to avoid hyperuricemia while controlling blood pressure. Switching to chlorthalidone may worsen uric acid; adding indomethacin risks interactions; spironolactone needs monitoring. ACC/AHA guidelines suggest calcium channel blockers as alternatives. Patient-centered care includes diet counseling to manage gout and hypertension outcomes.

Question 6

1. Recommend reducing amlodipine to 5 mg by mouth daily and consider titrating losartan upward if needed (correct answer)
2. Add furosemide 40 mg by mouth daily to treat edema and keep amlodipine at 10 mg
3. Add ibuprofen 600 mg by mouth three times daily to reduce swelling
4. Continue amlodipine 10 mg and start verapamil extended-release 240 mg by mouth daily

Explanation: This question tests management of calcium channel blocker adverse effects. The key patient-specific factor is ankle edema post-amlodipine dose increase, with controlled blood pressure and occupational standing. Reducing amlodipine to 5 mg and considering losartan titration is best to alleviate edema while maintaining control. Adding furosemide is unnecessary; ibuprofen worsens edema; adding verapamil risks bradycardia. ACC/AHA guidelines support dose adjustment for tolerance. Patient-centered care addresses lifestyle factors like standing for edema prevention.

Question 7

1. Start prednisone 40 mg by mouth daily for 5 days (correct answer)
2. Start amoxicillin 500 mg by mouth three times daily for 10 days
3. Start fluticasone nasal spray 2 sprays per nostril daily
4. Start theophylline extended-release 600 mg by mouth daily as first-line acute therapy

Explanation: This question tests management of non-infectious COPD exacerbations. The key patient-specific factor is acute dyspnea post-viral infection without purulence, in a patient with osteoporosis. Starting prednisone 40 mg daily for 5 days is best as short-course systemic corticosteroids are recommended for acute exacerbations per GOLD guidelines. Amoxicillin is unnecessary without infection; fluticasone nasal is for rhinitis; theophylline is not first-line due to toxicity. Guidelines aim to reduce symptoms and relapse. Patient-centered care considers osteoporosis risk with steroids and promotes adherence for better control.

Question 8

1. Start atorvastatin 40 mg by mouth nightly (correct answer)
2. Start fenofibrate 145 mg by mouth daily as monotherapy
3. Start ezetimibe 10 mg by mouth daily as first-line monotherapy
4. Defer therapy because he is under age 55 and has no cardiovascular disease

Explanation: This question tests primary prevention statin therapy selection in a diabetic patient. The key patient-specific factor is diabetes mellitus in a patient aged 40-75 years, which automatically qualifies him for moderate-to-high intensity statin therapy regardless of calculated ASCVD risk. Atorvastatin 40 mg is the best choice as it provides high-intensity therapy appropriate for diabetic patients with additional risk factors (low HDL, elevated triglycerides). Fenofibrate monotherapy (B) primarily targets triglycerides but lacks the robust cardiovascular outcome data of statins. Ezetimibe monotherapy (C) is less effective than statins for primary prevention. Deferring therapy (D) is incorrect because diabetes alone warrants statin initiation in this age group. The clinical pearl is that all diabetic patients aged 40-75 should receive at least moderate-intensity statin therapy, with high-intensity statins preferred when additional ASCVD risk factors are present, following ACC/AHA cholesterol guidelines.

Question 9

1. Continue warfarin unchanged and recheck international normalized ratio in 4–6 weeks
2. Hold warfarin for the entire antibiotic course without international normalized ratio monitoring
3. Arrange earlier international normalized ratio monitoring (within 3–5 days) and anticipate warfarin dose reduction during therapy (correct answer)
4. Add aspirin 81 mg daily to offset the interaction-related clotting risk

Explanation: This question tests management of a significant drug interaction between warfarin and trimethoprim/sulfamethoxazole. The key patient-specific factor is the need for antibiotic therapy in a stable warfarin patient, where TMP/SMX inhibits warfarin metabolism and can dramatically increase INR. Arranging early INR monitoring with anticipated dose reduction is optimal because this interaction typically increases INR by 1.5-2 points within 3-5 days. Continuing unchanged (A) risks dangerous supratherapeutic INR and bleeding. Holding warfarin completely (B) may lead to subtherapeutic anticoagulation and stroke risk. Adding aspirin (D) increases bleeding risk without addressing the interaction. The clinical framework for managing warfarin interactions includes early monitoring, preemptive dose adjustments for known significant interactions, and close follow-up, with TMP/SMX being one of the highest-risk antibiotics requiring proactive management.

Question 10

1. Continue simvastatin and add coenzyme Q10; no other changes needed
2. Stop simvastatin and switch to pravastatin 40 mg by mouth nightly; avoid grapefruit juice (correct answer)
3. Increase simvastatin to 80 mg by mouth nightly for better low-density lipoprotein cholesterol lowering
4. Add gemfibrozil 600 mg by mouth twice daily to treat myalgias

Explanation: This question tests the management of statin-induced myopathy. The key patient-specific factor is elevated creatine kinase with muscle pain and grapefruit juice consumption, which increases simvastatin exposure. Stopping simvastatin and switching to pravastatin 40 mg nightly while avoiding grapefruit is best as pravastatin has lower interaction risk and equivalent efficacy. Continuing with coenzyme Q10 does not address the cause; increasing simvastatin worsens risk; adding gemfibrozil increases myopathy risk. ACC/AHA guidelines recommend switching statins for intolerance. Patient-centered care involves lifestyle adjustments and monitoring symptoms for safe lipid management.

Question 11

1. Recommend adding dextromethorphan as needed and continue lisinopril
2. Recommend switching lisinopril to losartan 50 mg by mouth daily (correct answer)
3. Recommend switching lisinopril to aliskiren 150 mg by mouth daily
4. Recommend increasing lisinopril to 40 mg by mouth daily to overcome tolerance

Explanation: This question tests the management of adverse effects from antihypertensive medications, specifically ACE inhibitor-induced cough. The key patient-specific factor is the new persistent dry cough starting after lisinopril initiation, with controlled blood pressure and no other respiratory issues. Switching lisinopril to losartan 50 mg daily is the best choice as ARBs do not cause cough and provide equivalent antihypertensive efficacy. Adding dextromethorphan continues the offending agent; aliskiren is not preferred due to similar mechanism; increasing lisinopril may worsen cough. ACC/AHA guidelines recommend ARBs as alternatives for ACE inhibitor intolerance. Patient-centered care includes monitoring for resolution of symptoms and blood pressure control to prevent long-term complications.

Question 12

1. Recommend discontinuing niacin and optimizing statin therapy instead (correct answer)
2. Recommend doubling niacin dose to 1000 mg three times daily to build tolerance
3. Recommend adding allopurinol for uric acid and continuing niacin unchanged
4. Recommend switching atorvastatin to gemfibrozil and continuing niacin

Explanation: This question tests management of niacin adverse effects in dyslipidemia. The key patient-specific factor is flushing with immediate-release niacin, elevated uric acid, and concurrent statin use. Recommending discontinuation of niacin and optimizing statin is best as niacin adds limited benefit and significant side effects per guidelines. Doubling dose worsens flushing; adding allopurinol treats symptomatically; switching to gemfibrozil increases myopathy risk. ACC/AHA guidelines de-emphasize niacin due to risks. Patient-centered care focuses on alcohol reduction and statin titration for effective lipid control.

Question 13

1. Start atorvastatin 40 mg by mouth nightly (correct answer)
2. Start omega-3 ethyl esters 4 g/day by mouth
3. Start gemfibrozil 600 mg by mouth twice daily
4. No lipid therapy is indicated because low-density lipoprotein cholesterol is <130 mg/dL

Explanation: This question tests lipid management in patients with diabetes without ASCVD. The key patient-specific factor is T2DM duration over 8 years with LDL-C 118 mg/dL, warranting statin therapy regardless of calculated risk. Starting atorvastatin 40 mg nightly is the best choice as moderate-intensity statins are recommended for adults 40–75 with diabetes per ACC/AHA guidelines. Omega-3 and gemfibrozil target triglycerides but not LDL-C primarily; no therapy ignores guidelines. Guidelines aim for LDL-C reduction to lower cardiovascular risk in diabetes. Patient-centered care includes exercise encouragement and monitoring for statin side effects to enhance adherence and outcomes.

Question 14

1. Continue both apixaban and warfarin to maximize stroke prevention
2. Identify therapeutic duplication and contact the prescriber to discontinue one anticoagulant (correct answer)
3. Increase warfarin dose to target an international normalized ratio of 4–5
4. Add aspirin 81 mg by mouth daily for additional anticoagulation

Explanation: This question tests the identification of therapeutic duplication in anticoagulation therapy. The key patient-specific factor is concurrent use of warfarin and apixaban, increasing bleeding risk in an elderly patient with atrial fibrillation. Identifying duplication and contacting the prescriber to discontinue one is essential to prevent hemorrhage. Continuing both or adding aspirin heightens risk; increasing warfarin targets inappropriate INR. ACC/AHA guidelines prohibit dual anticoagulation without indication. Patient-centered care includes medication reconciliation and alcohol counseling to minimize bleeding and improve safety.

Question 15

1. Start rosuvastatin 10 mg by mouth daily (correct answer)
2. Start simvastatin 80 mg by mouth nightly
3. Start colesevelam 3.75 g by mouth daily as first-line monotherapy
4. Defer statin therapy because the 10-year ASCVD risk is <10%

Explanation: This question tests lipid-lowering therapy in high-risk patients without ASCVD. The key patient-specific factor is LDL-C 168 mg/dL with 8.5% ASCVD risk, HIV, and family history warranting statin initiation. Starting rosuvastatin 10 mg daily is appropriate as moderate-intensity statins are recommended for ≥7.5% risk per ACC/AHA guidelines, with rosuvastatin having fewer interactions. Simvastatin 80 mg is not recommended; colesevelam is not first-line; deferring ignores risk. Guidelines prioritize statins for primary prevention. Patient-centered care includes family history consideration and monitoring for adherence.

Question 16

1. Add spironolactone 25 mg by mouth daily to improve blood pressure
2. Counsel to stop potassium-containing salt substitutes and contact prescriber to evaluate hyperkalemia while continuing losartan (correct answer)
3. Increase losartan to 200 mg by mouth daily
4. Add potassium chloride 20 mEq by mouth daily due to chlorthalidone use

Explanation: This question tests the selection of appropriate therapy modifications in a patient with hypertension, type 2 diabetes, chronic kidney disease (CKD), and hyperkalemia while on an angiotensin receptor blocker (ARB). The key patient-specific factors influencing therapy choice are the elevated serum potassium of 5.6 mEq/L, frequent use of potassium-containing salt substitutes, high-potassium diet, reduced eGFR of 48 mL/min/1.73 m², and ongoing losartan therapy. Counseling the patient to stop potassium-containing salt substitutes and contacting the prescriber to evaluate hyperkalemia while continuing losartan is the best choice because it addresses a modifiable dietary contributor to hyperkalemia without discontinuing the ARB, which provides renal protection in diabetic nephropathy. Adding spironolactone is incorrect as it is a potassium-sparing diuretic that would exacerbate hyperkalemia, and increasing losartan to 200 mg daily is suboptimal because it exceeds the maximum recommended dose of 100 mg and could worsen hyperkalemia. Adding potassium chloride is inappropriate and dangerous given the existing hyperkalemia, despite chlorthalidone's potential to cause hypokalemia, as the net effect here is elevated potassium. A key clinical pearl is that guidelines from the American Diabetes Association and Kidney Disease: Improving Global Outcomes recommend ARBs like losartan for patients with diabetes, albuminuria, and CKD to slow disease progression, but regular monitoring of potassium and patient education on low-potassium diets are essential for safety. This patient-centered approach balances evidence-based renoprotection with minimizing risks like hyperkalemia, potentially improving long-term outcomes such as reduced albuminuria and preserved renal function.

Question 17

1. Target 5%–10% weight loss through calorie reduction and at least 150 minutes/week of moderate-intensity physical activity (correct answer)
2. Use a ketogenic diet only; physical activity is unnecessary for diabetes prevention
3. Replace sugar-sweetened beverages with fruit juice to reduce diabetes risk
4. Begin high-dose vitamin D supplementation as the primary prevention strategy

Explanation: This question tests lifestyle interventions for prediabetes prevention in obesity. The key patient-specific factor is high BMI with poor diet and inactivity increasing diabetes risk. Targeting 5–10% weight loss through calorie reduction and 150 minutes/week activity is prioritized as it delays diabetes onset per ADA guidelines. Ketogenic diet without activity is unbalanced; replacing with juice maintains sugar; vitamin D is not primary. Guidelines support intensive lifestyle changes. Patient-centered care addresses sleep and eating habits for sustainable prevention.

Question 18

1. Continue all medications; add potassium chloride 10 mEq by mouth daily only
2. Hold metoprolol succinate and contact prescriber due to bradycardia/hypotension risk (correct answer)
3. Increase furosemide to 80 mg by mouth daily to improve congestion
4. Add spironolactone 25 mg by mouth daily despite potassium 3.3 mEq/L and eGFR 35

Explanation: This question tests the identification and modification of therapy in heart failure with reduced ejection fraction (HFrEF) considering drug interactions and vital signs. The key patient-specific factor is bradycardia, hypotension, and dizziness in an elderly patient on multiple negative chronotropic agents like metoprolol, amiodarone, and newly added levofloxacin. Holding metoprolol succinate and contacting the prescriber is necessary to mitigate risks of bradycardia and hypotension. Adding potassium ignores cardiac risks; increasing furosemide may worsen hypotension; adding spironolactone is inappropriate with low potassium and eGFR. ACC/AHA heart failure guidelines emphasize deprescribing in polypharmacy to avoid adverse events. Patient-centered care involves balancing infection treatment with fall prevention and monitoring electrolytes for optimal outcomes.

Question 19

1. Start prednisone 40 mg by mouth daily for 5 days plus amoxicillin/clavulanate 875/125 mg by mouth twice daily for 5–7 days (correct answer)
2. Start azithromycin 500 mg by mouth on day 1, then 250 mg daily for 4 days
3. Start codeine/guaifenesin syrup for cough and hold albuterol
4. Start montelukast 10 mg by mouth nightly

Explanation: This question tests pharmacologic management of COPD exacerbations with infection signs. The key patient-specific factor is purulent sputum, fever, and azithromycin allergy in a COPD patient. Starting prednisone 40 mg daily for 5 days plus amoxicillin/clavulanate is best as it covers common pathogens and reduces inflammation per GOLD guidelines. Azithromycin is contraindicated; codeine suppresses cough inappropriately; montelukast lacks acute efficacy. Guidelines support antibiotics for purulent exacerbations to prevent hospitalization. Patient-centered care includes vaccination updates and smoking history review for better prognosis.

Question 20

1. Encourage pursed-lip breathing and assess for triggers while advising urgent evaluation if symptoms worsen or oxygen saturation drops (correct answer)
2. Recommend complete bed rest and avoidance of any physical activity for 2 weeks
3. Recommend increasing caffeine intake to improve breathing
4. Recommend using a cool-mist humidifier as the only intervention and avoid medical evaluation

Explanation: This question tests non-pharmacologic management of mild COPD exacerbations. The key patient-specific factor is increased dyspnea without signs of infection, with stable oxygen saturation and correct inhaler use. Encouraging pursed-lip breathing and assessing triggers with urgent evaluation advice is prioritized as it supports self-management in stable exacerbations. Complete bed rest may lead to deconditioning; increasing caffeine lacks evidence; humidifier alone ignores monitoring needs. GOLD guidelines recommend breathing techniques and trigger avoidance for mild exacerbations. Patient-centered care emphasizes education on warning signs and smoking cessation to prevent severe episodes and improve quality of life.